AUTHORS
Stephen Martindale, BA, Kadriye Nehir Cosgun, PhD2, Kohei Kume, PhD3, Takeshi Ito, MD-PhD4, Etienne Leveille, MD5, Anna Mathew Lawrence6, Thierry Bertomeu, PhD7, Markus Müschen, MD-PhD8
AFFILIATIONS
1 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
2 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
3 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
4 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
5 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
6 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
7 ChemoGenix: the pooled genome-wide KO CRISPR/Cas9 screening platform of the Institute for Research in Immunology and Cancer, Montréal, Canada
8 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
ABSTRACT
Background and Significance: Although alterations in the PI3K pathway account for ~25% of somatic driver lesions across human cancers, prior work from our group and others has shown that B-cell malignancies arising from pre-germinal center (GC) stages -including B-cell acute lymphoblastic leukemia (B-ALL), mantle cell lymphoma, and IGHV-unmutated chronic lymphocytic leukemia -cannot tolerate PI3K hyperactivation. For example, PTEN inactivation is frequent across the cancer spectrum but conspicuously absent from these malignancies, suggesting that they require PI3K signaling to remain within a narrow “Goldilocks zone.”
Results: To determine why B-ALL cells are uniquely sensitive to PI3K hyperactivation, we performed a whole-genome CRISPR knockout screen in human B-ALL cells carrying an inducible PTEN deletion. The top rescue hits were dominated by core components of the pre-B-cell receptor (pre-BCR) signaling complex, including IGLL1, which encodes the surrogate light-chain subunit λ5, as well as CD79A, CD79B, CD81, and SYK. These findings identified pre-BCR assembly and signaling as central determinants of sensitivity to PI3K hyperactivation. We focused on IGLL1, the highest-ranking pre-BCR hit, whose product λ5 pairs with VPREB1 and the immunoglobulin heavy chain (IgH) to assemble the pre-BCR.
To validate this finding, we generated IGLL1-knockout clones in pre-BCR⁺ B-ALL cells. The PTEN inhibitor SF1670 markedly increased AKT-T308 phosphorylation and induced cell death in wild-type cells. In contrast, IGLL1 deletion abrogated SF1670-induced AKT phosphorylation and cell death. Doxycycline-inducible reconstitution of IGLL1 restored sensitivity to SF1670, phenocopying wild-type cells. To determine whether this phenotype was specific to λ5 or could be recapitulated by disrupting another surrogate light-chain component, we generated VPREB1-knockout clones. These cells exhibited only partial resistance to SF1670, demonstrating that loss of λ5, but not VpreB1 alone, confers full resistance to PI3K hyperactivation following PTEN inhibition.
We next used flow cytometry to determine whether λ5 and VpreB1 are individually required for surface expression of their partner subunit. VPREB1-knockout cells retained surface λ5 expression, whereas IGLL1-knockout cells lacked detectable surface VPREB1. Thus, λ5 is required for surface expression of VPREB1 and serves as the central scaffold for surrogate light-chain assembly.
We next asked whether the surrogate light chain could engage the pre-BCR signaling complex independently of IgH. Flow cytometry of IGH-knockout B-ALL cells demonstrated persistent surface expression of λ5 and VpreB1, indicating that surrogate light-chain assembly at the cell surface does not require IgH. Co-immunoprecipitation of VpreB1 revealed its association with both λ5 and CD79A in wild-type and IGH-knockout cells, demonstrating that the surrogate light chain remains associated with the pre-BCR signaling machinery in the absence of IgH. To test whether λ5 engagement was sufficient to activate signaling, we stimulated wild-type cells with an anti-λ5 antibody. Phosphoproteomic analysis revealed increased phosphorylation of SYK-Y352, BTK-Y223, AKT-T308/S473, and ERK-T202/Y204 within 30 minutes.
To further interrogate λ5-dependent signaling, we engineered wild-type and IGH-knockout B-ALL cells to stably express the GCaMP6s biosensor, enabling real-time measurement of intracellular Ca²⁺ flux. Autonomous Ca²⁺ oscillations of similar amplitude and frequency were observed in both genotypes. Moreover, anti-λ5 stimulation elicited a rapid increase in intracellular Ca²⁺ with comparable magnitude and kinetics in wild-type and IGH-knockout cells. Together with the co-immunoprecipitation results, these findings demonstrate that λ5-containing surrogate light-chain complexes can engage CD79A and activate downstream signaling independently of IgH.
Conclusions: Our findings identify λ5, encoded by IGLL1, as the central organizing subunit of the surrogate light chain and a critical determinant of the PI3K-AKT signaling threshold that governs sensitivity to PTEN inhibition in B-ALL. Co-immunoprecipitation, phosphoproteomic, and calcium-flux studies further establish that λ5-containing complexes can assemble with and activate the pre-BCR signaling machinery independently of IgH. These findings position therapeutic engagement of λ5 as a strategy to drive PI3K signaling beyond its tolerable threshold in B-ALL.
DISCLOSURES
Stephen Martindale, BA: No relevant conflicts of interest to declare.